FDA Approves Expandable Heart Valve for Children

The U.S. Food and Drug Administration (FDA) has approved the Autus Size-Adjustable Valve, the first artificial heart valve designed to expand post-surgery, eliminating the need for multiple replacement operations in pediatric patients. Developed by Edwards, this artificial pulmonary valve is intended for children with certain congenital heart defects.

Congenital heart disease affects approximately 400,000 children born in the U.S. annually, with around 30 percent of these cases impacting heart valves. Specifically, pulmonary valve abnormalities like stenosis and atresia affect about 4,200 babies each year. Traditional artificial valves require repeated surgeries as a child grows, posing significant risks.

The Autus valve can be implanted as small as 13 millimeters in toddlers and preschool-aged children, and expanded to a maximum of 22 millimeters using a balloon catheter, matching adult valve sizes. This innovation also marks the first use of polymeric material for the valve flaps, a departure from animal-derived synthetic flaps that tend to harden and break down faster in children. FDA follow-up data after one year indicates the Autus valve demonstrates better durability.

What to watch: Continued monitoring of Autus valve's long-term durability and patient outcomes.

Editor's note: The article accurately synthesizes the technical specifications and clinical benefits of the new valve as described in the source.

This article is AI-generated and fact-gated. Original reporting: Engadget